Dominik Sturm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7300373/publications.pdf

Version: 2024-02-01

94	19,378	46918 47	49773 87
papers	citations	h-index	g-index

99	99	99	19194
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Primary central nervous system sarcoma with DICER1 mutationâ€"treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer, 2022, 128, 697-707.	2.0	14
2	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	2.4	12
3	A Systematic Review and Meta-Analysis of Malignant Rhabdoid and Small Cell Undifferentiated Liver Tumors: A Rational for a Uniform Classification. Cancers, 2022, 14, 272.	1.7	5
4	ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant. Pediatric Blood and Cancer, 2022, 69, e29594.	0.8	0
5	Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas. International Journal of Cancer, 2022, 151, 1431-1446.	2.3	6
6	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	0.6	1
7	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. Neuro-Oncology, 2022, 24, i154-i154.	0.6	0
8	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Neuro-Oncology, 2022, 24, i61-i62.	0.6	0
9	DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. Acta Neuropathologica, 2022, 144, 129-142.	3.9	5
10	HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma. Neuro-Oncology, 2022, 24, i76-i76.	0.6	0
11	Clinical characteristics and outcome of a large cohort of patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Journal of Clinical Oncology, 2022, 40, 2052-2052.	0.8	0
12	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathologica, 2021, 141, 85-100.	3.9	52
13	Accurate calling of KIAA1549â€BRAF fusions from DNA of human brain tumours using methylation arrayâ€based copy number and gene panel sequencing data. Neuropathology and Applied Neurobiology, 2021, 47, 406-414.	1.8	12
14	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro-Oncology, 2021, 23, 34-43.	0.6	75
15	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€"Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	7.7	39
16	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	0.6	22
17	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	3.9	36
18	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	3.9	33

#	Article	IF	Citations
19	Spontaneous regression of a congenital high-grade glioma â€“ a case report. Neuro-Oncology Advances, 2021, 3, vdab120.	0.4	1
20	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nature Communications, 2021, 12, 5530.	5.8	24
21	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica, 2021, 142, 1065-1069.	3.9	16
22	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
23	Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort. Frontiers in Oncology, 2021, 11, 756025.	1.3	3
24	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 97-104.	1.2	29
25	Diffuse glioneuronal tumour with oligodendrogliomaâ€like features and nuclear clusters (DGONC) â€“ a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathology and Applied Neurobiology, 2020, 46, 422-430.	1.8	51
26	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	13.5	93
27	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	13.7	94
28	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	7.7	157
29	HGG-56. EXTENSIVE MOLECULAR HETEROGENEITY WITHIN H3-/IDH-WILDTYPE PEDIATRIC GLIOBLASTOMA. Neuro-Oncology, 2020, 22, iii354-iii354.	0.6	0
30	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. Neuro-Oncology, 2020, 22, iii311-iii311.	0.6	0
31	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathologica, 2019, 138, 827-835.	3.9	42
32	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. American Journal of Neuroradiology, 2019, 40, 1811-1817.	1.2	9
33	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. Neuro-Oncology, 2019, 21, ii82-ii82.	0.6	2
34	A simplified approach using Taqman low-density array for medulloblastoma subgrouping. Acta Neuropathologica Communications, 2019, 7, 33.	2.4	18
35	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. Acta Neuropathologica, 2019, 137, 847-850.	3.9	7
36	Occurrence of highâ€grade glioma in Noonan syndrome: Report of two cases. Pediatric Blood and Cancer, 2019, 66, e27625.	0.8	11

#	Article	IF	Citations
37	Ectopic intracranial retinoblastoma in a 3.5â€monthâ€old infant without eye involvement and without evidence of heritability. Pediatric Blood and Cancer, 2019, 66, e27599.	0.8	3
38	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. Cancer Cell, 2019, 35, 95-110.e8.	7.7	65
39	Integrated molecular characterization of <scp>IDH</scp>â€mutant glioblastomas. Neuropathology and Applied Neurobiology, 2019, 45, 108-118.	1.8	68
40	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	13.7	1,068
41	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
42	Gliomas in Children. Seminars in Neurology, 2018, 38, 121-130.	0.5	15
43	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathology, 2018, 28, 656-662.	2.1	89
44	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology, 2018, 20, 123-131.	0.6	184
45	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	0.8	250
46	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making â€" A Selected Case Series. Klinische Padiatrie, 2018, 230, 305-313.	0.2	8
47	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	5.1	268
48	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	3.9	104
49	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	1.4	42
50	Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. European Journal of Cancer, 2017, 73, 38-47.	1.3	101
51	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathologica, 2017, 134, 507-516.	3.9	144
52	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. Acta Neuropathologica, 2017, 134, 155-158.	3.9	26
53	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	5.1	586
54	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. Clinical Sarcoma Research, 2017, 7, 9.	2.3	51

#	Article	IF	Citations
55	Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. Journal of Clinical Oncology, 2017, 35, 2370-2377.	0.8	223
56	The Î²-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner. Oncotarget, 2017, 8, 27300-27313.	0.8	35
57	High-grade glioma in very young children: a rare and particular patient population. Oncotarget, 2017, 8, 64564-64578.	0.8	38
58	No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. Klinische Padiatrie, 2016, 228, 113-117.	0.2	44
59	Evidence of H3 K27M mutations in posterior fossa ependymomas. Acta Neuropathologica, 2016, 132, 635-637.	3.9	73
60	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nature Medicine, 2016, 22, 1314-1320.	15.2	183
61	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	3.9	203
62	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	7.7	438
63	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
64	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathologica, 2016, 131, 137-146.	3.9	162
65	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. Neuropathology, 2015, 35, 538-544.	0.7	38
66	Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles. Brain Pathology, 2015, 25, 202-208.	2.1	66
67	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	3.9	277
68	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell, 2015, 28, 715-729.	7.7	90
69	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	9.4	381
70	Oncolytic effects of parvovirus Hâ€1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. International Journal of Cancer, 2014, 134, 703-716.	2.3	22
71	Revealing the role of SGK1 in the dynamics of medulloblastoma using a mathematical model. Journal of Theoretical Biology, 2014, 354, 105-112.	0.8	1
72	Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics. Neuroscience, 2014, 264, 171-185.	1.1	45

#	Article	IF	Citations
73	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627
74	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	12.8	469
75	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathologica, 2014, 128, 279-289.	3.9	191
76	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	3.9	176
77	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	13.7	520
78	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	9.4	674
79	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	3.9	254
80	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	7.7	633
81	Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant <scp>H</scp>istone 3 Tail. Brain Pathology, 2013, 23, 210-216.	2.1	74
82	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathologica, 2013, 125, 659-669.	3.9	250
83	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature Medicine, 2013, 19, 901-908.	15.2	388
84	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Child's Nervous System, 2013, 29, 1253-1262.	0.6	12
85	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	0.8	381
86	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 2012, 124, 439-447.	3.9	799
87	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	7.7	1,551
88	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	13.7	2,129
89	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	13.7	765
90	FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. Journal of Clinical Oncology, 2011, 29, 3852-3861.	0.8	143

#	Article	IF	Citations
91	Reply to J.C. Lindsey et al. Journal of Clinical Oncology, 2011, 29, e348-e349.	0.8	2
92	TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. Journal of Clinical Oncology, 2010, 28, 5188-5196.	0.8	100
93	Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification. Journal of Clinical Oncology, 2010, 28, 3054-3060.	0.8	136
94	Novel oncogene amplifications in tumors from a family with Liâ€“Fraumeni syndrome. Genes Chromosomes and Cancer, 2009, 48, 558-568.	1.5	13